These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21818557)

  • 1. Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer.
    Umemura S; Yamane H; Suwaki T; Katoh T; Yano T; Shiote Y; Takigawa N; Kiura K; Kamei H
    J Cancer Res Clin Oncol; 2011 Oct; 137(10):1469-75. PubMed ID: 21818557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study.
    Hamada T; Yasunaga H; Nakai Y; Isayama H; Matsui H; Fushimi K; Koike K
    Respirology; 2016 Feb; 21(2):338-43. PubMed ID: 26775618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer.
    Nishimura M; Toyoda M; Takenaka K; Imamura Y; Chayahara N; Kiyota N; Mukohara T; Kotake T; Tsuji A; Saito K; Saito Y; Minami H
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1165-70. PubMed ID: 27100735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease.
    Choi MK; Hong JY; Chang W; Kim M; Kim S; Jung HA; Lee SJ; Park S; Chung MP; Sun JM; Park K; Ahn MJ; Ahn JS
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1217-25. PubMed ID: 24696125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104).
    Takeda K; Negoro S; Tamura T; Nishiwaki Y; Kudoh S; Yokota S; Matsui K; Semba H; Nakagawa K; Takada Y; Ando M; Shibata T; Saijo N
    Ann Oncol; 2009 May; 20(5):835-41. PubMed ID: 19164456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Severe interstitial pneumonitis related to Gemcitabine].
    Sabria-Trias J; Bonnaud F; Sioniac M
    Rev Mal Respir; 2002 Oct; 19(5 Pt 1):645-7. PubMed ID: 12473953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients.
    Takeda T; Sasaki T; Fukuda K; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
    Int J Clin Oncol; 2021 Mar; 26(3):543-551. PubMed ID: 33175298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
    Irie H; Suzuki R; Takagi T; Sugimoto M; Konno N; Sato Y; Hikichi T; Nakamura J; Hashimoto M; Ohira H
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):517-523. PubMed ID: 31691078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
    Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
    Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine-induced pulmonary toxicity: case report and review of the literature.
    Gupta N; Ahmed I; Steinberg H; Patel D; Nissel-Horowitz S; Mehrotra B
    Am J Clin Oncol; 2002 Feb; 25(1):96-100. PubMed ID: 11823707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
    Saito Y; Sasaki S; Oikado K; Tominaga J; Sata M; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
    Cancer Sci; 2021 Apr; 112(4):1495-1505. PubMed ID: 33098725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe pulmonary toxicity in a patient treated with gemcitabine.
    Rosado MF; Kett DH; Schein RM; Baraona FJ; Sridhar KS
    Am J Clin Oncol; 2002 Feb; 25(1):31-3. PubMed ID: 11823691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.
    Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A
    Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy.
    Li F; Liu H; Wu H; Liang S; Xu Y
    Radiat Oncol; 2021 Apr; 16(1):70. PubMed ID: 33849579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
    Noble S; Goa KL
    Drugs; 1997 Sep; 54(3):447-72. PubMed ID: 9279506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
    Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
    Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
    Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
    J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
    Cappuzzo F; Novello S; De Marinis F; Selvaggi G; Scagliotti GV; Barbieri F; Maur M; Papi M; Pasquini E; Bartolini S; Marini L; Crinò L
    Lung Cancer; 2006 Jun; 52(3):319-25. PubMed ID: 16630670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine pulmonary toxicity: CT features.
    Boiselle PM; Morrin MM; Huberman MS
    J Comput Assist Tomogr; 2000; 24(6):977-80. PubMed ID: 11105721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.